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Mitochondrial DNA (mtDNA) haplogroups have been associated with the expression of mitochondrial-related diseases and with
metabolic alterations, but their role has not yet been investigated in morbid obese Caucasian subjects. Terefore, we investigated
the association between mitochondrial haplogroups and morbid obesity in patients from southern Italy. Te mtDNA D-loop of
morbid obese patients (푛 = 500; BMI > 40 kg/m2) and controls (푛 = 216; BMI < 25 kg/m2) was sequenced to determine themtDNA
haplogroups. Te T and J haplogroup frequencies were higher and lower, respectively, in obese subjects than in controls. Women
bearing haplogroup T or J had twice or half the risk of obesity. Binomial logistic regression analysis showed that haplogroup T and
systolic blood pressure are risk factors for a high degree of morbid obesity, namely, BMI > 45 kg/m2 and in fact together account for
8% of the BMI. In conclusion, our _nding that haplogroup T increases the risk of obesity by about two-fold, suggests that, besides
nuclear genome variations and environmental factors, the T haplogroup plays a role in morbid obesity in our study population
from southern Italy.
1. Introduction
Obesity is a multifactorial disorder caused by a combination
of environmental, behavioural, and genetic factors; however,
themolecularmechanisms by which these factors provoke fat
mass accumulation and maintenance are not yet completely
elucidated [1]. Moreover, mitochondrial dysfunctions that
result in lipid accumulation and insulin resistance have
been implicated in the pathogenesis of obesity [2]. Several
mitochondrial DNA (mtDNA) variants have been investi-
gated in diverse populations with obesity-related and lipid
metabolism alterations [3, 4], and it was suggested that
particular mtDNA haplogroups could be associated with
ineccient energy expenditure [5]. A mitochondrial hap-
logroup (mt-haplogroup) is a collection of single nucleotide
polymorphisms [6] accumulated throughout human history
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in speci2c populations that could be attributed to genetic dri6
and/or climate selection [7–9]. Mitochondrial haplogroups
have been associated with the expression of mitochondrial-
related diseases (metabolic syndrome, type 2 diabetes, neu-
rological disorders, infertility, and Parkinson’s disease) and
with various individual characteristics (aging and endurance
training capacity) [3, 10–14], but, to our knowledge, their
role has not yet been investigated in morbid obese Caucasian
subjects. We previously reported that several DNA variants
and epigenetic alterations are associated with the obese phe-
notype and/or with obese-related diseases [15–19]. Here, we
have characterized mt-haplogroups in a large population of
morbid obese adults and nonobese individuals from southern
Italy to look for associations among speci2c mt-haplogroups
and the obese phenotype.
2. Methods
2.1. Study Population. Five hundred unrelated morbid obese
patients (64% females, age range 17–70 years, median; 2.5th–
97.5th percentiles BMI = 45.1; 38.2–65.4 kg/m2), and 216 non
obese controls (66% females, age range 26–76 years, BMI
= 22.9; 18.2–25.6 kg/m2) were recruited from the Obesity
Outpatient Clinic of the Dipartimento di Medicina Clinica
e Chirurgia and from the Dipartimento di Medicina Moleco-
lare e BiotecnologieMediche, Federico IIUniversityHospital,
Naples (Italy), respectively. All participants were Caucasians
and had lived in southern Italy for at least 3 generations.
Written informed consent for participation in the study was
obtained from all subjects. `e research was approved by the
Ethics Committee of the School of Medicine, University of
Naples Federico II, and was in accordance with the principles
of the Helsinki II Declaration.
2.2. Laboratory Investigations. Two blood samples (one for
biochemical analysis and one for DNA extraction) were
obtained a6er an overnight fast from each enrolled subject.
Biochemical parameters were measured enzymatically with
routine methods on an automated analyzer (Hitachi 747;
Boehringer Mannheim, Germany). Insulin resistance was
estimated in obese subjects with the homeostasis model
assessment (HOMA) and the formula: fasting insulin (mU/L)
X fasting glucose (mmol/L)/22.5.
`e clinical and anamnestic data of each obese subject
were collected, and the main metabolic parameters were
evaluated. Fat mass (FM) and fat-free mass (FFM) were
measured by bioimpedentiometry (Sta/BIA Akern, Florence,
Italy) and respiratory quotient (RQ) and basal metabolic
rate (BMR) by indirect calorimetry (Sensor Medics Vmax29,
Anaheim, CA, USA). `e BMI was calculated as weight
(kg)/square height (m2). Systolic and diastolic blood pres-
sure, and cardiac frequency (beats/min) were collected by
standard procedures. Metabolic syndrome (MS), which is a
cluster of metabolic risk factors, namely, abdominal obesity,
dyslipidemia (hypertriglyceridemia or low HDL-cholesterol
concentrations), elevated blood pressure, and hyperglycemia,
as de2ned by the American Heart Association criteria, was
diagnosed if 3 out of the 5 risk factors were present [20].
2.3. Mitochondrial DNA Ampli?cation and Sequencing.
Genomic DNA was extracted from whole blood (Illustra
BACC-2; GE Healthcare, UK). `e D-loop region (about
1100 bp) was ampli2ed with primers (HVI-forward:
GTAAACCGGAGATGAAAACCT; HVII-reverse
ACTGCATACCGCCAAAAGATA) chosen by the PRIMER
3 program (http://frodo.wi.mit.edu/) in a 2nal volume of
25 휇L containing a PCR mixture (10 휇M each primer, 10x
PCR buler, 200휇M each deoxynucleotide triphosphate,
and 0.5U of Taq DNA polymerase) and 50 ng of genomic
DNA. PCR consisted of an initial denaturation at 95∘C for
5min, followed by 35 cycles of 95∘C for 30 s, 60∘C for 1min,
and 72∘C for 1min, followed by a 2nal extension at 72∘C
for 5min. `e PCR fragment was run on a 1.5% agarose
gel, puri2ed, and sequenced in both directions (BigDye
Terminator v3.1 cycle sequencing method on an ABI-Prism
3730 DNA Analyzer; Applied Biosystems). Sequences were
assembled with the SeqScape program v.2.5. `e mtDNA
nucleotide sequences were numbered according to the rCRS
reference sequence (NC 012920). Haplogroups were de2ned
by nucleotides at speci2c known polymorphic sites in the
mtDNA [6].
2.4. Statistical Analysis. Haplogroup frequencies in patients
and control subjects were compared using the 휒2 test. A
푃 < 0.05 was considered the level of statistical signi2cance.
`e odds ratio (OR) and 95% con2dence intervals (CI)
values for each haplogroupwere calculated for the statistically
signi2cant haplogroup. ANOVA was performed to compare
metabolic parameters in the dilerent haplogroups. Multiple
comparisons were corrected with the Bonferroni test. `e
Student’s t-test, followed by a binomial logistic regression
analysis, was used to investigate the association between
the biochemical and clinical characteristics and the pres-
ence/absence of a speci2c haplogroup. Sample estimates were
veri2ed by bootstrapping. Statistical analyses were carried
out with the PASW package for Windows (Ver.18; SPSS Inc.
Headquarters, Chicago, Il, USA).
3. Results
`e clinical and biochemical characteristics of the obese sub-
jects are reported in Table 1. Metabolic syndrome was present
in 41.3% of our obese subjects and was signi2cantly more
frequent inmen than in women (47.9% versus 37.5%; OR/95%
CI = 1.17/1.01–1.35, 푃 = 0.031). Concurrent MS factors in
our obese patients were hypertriglyceridemia (OR/95% CI:
16.7/10.8–26.0), hyperglycemia (OR/95% CI: 8.5/5.6–12.8),
hypertension (OR/95% CI: 7.1/4.7–10.7), low serum levels
of HDL cholesterol (OR/95% CI: 5.1/3.6–7.4). Haplogroup
frequencies in obese and nonobese subjects are reported in
Table 2. All nine common European haplogroups (H, I, J,
K, T, U, V, W, and X) [21] were identi2ed in most of our
subjects (94.4%), whereas the R, L, N, B, and F haplogroups
(collectively indicated as “others” in Table 2) were rare (5.6%).
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European haplogroup frequencies were very similar in our
obese and nonobese subjects, and the H haplogroup was the
most frequent (about 40% of subjects).Ee T (푃 = 0.004) and
J (푃 = 0.02) haplogroup frequencies were higher and lower,
respectively, in obese subjects than in controls (haplogroup T:
13.2% versus 6%; haplogroup J: 5% versus 9.7%). At the휒2 test,
subjects with the T haplogroup had an increased risk of about
two-fold for obesity (OR/95%CI = 1.94/1.16–3.22;푃 = 0.004),
whereas subjects with the J haplogroup were less exposed to
obesity (OR/95%CI= 0.63/0.45–0.89;푃 = 0.02) than subjects
with the other haplogroups. Eese Zndings were conZrmed
by the results of bootstrap analysis based on 100 bootstrap
samples.
Whenwe divided our populations intomales and females, the
prevalence of the T and J haplogroups remained signiZcantly
higher and lower, respectively, in the obese females (12.4%
versus 4.9%, OR/95% CI = 2.18/1.01–4.39; 푃 = 0.012 for
haplogroup T; 4.7% versus 11.9%, OR/95% CI = 0.55/0.38–
0.78; 푃 = 0.009 for haplogroup J). In addition, the T hap-
logroup was correlated to the degree of obesity. In fact,
this haplogroup was signiZcantly more frequent in obese
subjects with a BMI higher than in those with a BMI lower
than the median BMI (45 kg/m2) (16% versus 10%, resp.;
푃 = 0.04). Binomial logistic regression analysis (dependent
variable: median BMI and independent variables: clinical
and biochemical investigated parameters) showed that hap-
logroup T and systolic blood pressure are risk factors for
a high degree of morbid obesity, namely, BMI > 45 kg/m2
(OR/95% CI: 2.3/1.3–4.3 and OR/95% CI: 1.1/1.02–1.4, resp.);
in fact together they account for 8% of the BMI. We did
not Znd an association between mtDNA haplogroups and
the clinical/biochemical tested variables, or in haplogroup
frequencies according to MS presence/absence.
4. Discussion
Mitochondrial DNA haplogroups have been associated with
metabolic disorders in various populations [3, 22, 23],
although not yet in morbid obese Caucasians from southern
Italy. Ee prevalence of MS in our obese patients (41%) was
similar to that previously reported in a multicenter Italian
study (43.6%) [24]. We found that haplogroup H was the
most common haplogroup in both obese and control subjects
(46.6% and 40.7%, resp.) from southern Italy, which is in
agreement with the H frequency reported in other European
populations (haplogroupH frequency: 13.3%–41.7%) [21].We
also show that haplogroups T and J conferred an increased
and decreased risk for obesity, respectively. Ee J haplogroup
was reported to protect against the onset of diseases related
to oxidative stress and/or low inaammation grade, such as
ischemic cardiomyopathy [25]. In fact, subjects bearing this
haplogroup showed lower oxygen consumption (because the
lower ebciency of the electron respiratory chain resulted in
reduced production of radical oxygen species) than those
with the H haplogroup [25].
On the other hand, subjects with haplogroup T could be
intrinsically prone to develop defects in the mitochondrial
oxidative phosphorylation system, which, in turn, negatively
Table 1: General and biochemical characteristics of the morbid




Age (years) 32.59 17.50 57.00
Height (m) 1.66 1.51 1.85
Weight (kg) 125.54 98.00 178.40
BMI (kg/m2) 45.10 38.20 65.40
Waist circumference (cm) 131.00 106.00 170.00
Hips circumference (cm) 134.00 114.90 158.10
W/H ratio 0.99 0.82 1.19
RQ 0.87 0.74 1.01
BMR (kcal) 2237.50 1581.38 3278.63
FFM (%) 51.40 40.28 64.11
FM (%) 48.55 35.89 59.73
SBP (mmHg) 124.45 100.00 160.00
DBP (mmHg) 80.00 60.00 100.00
Heart rate (beats/min) 80.00 60.00 100.00
Glucose (mmol/L) 5.05 3.89 7.53
Total cholesterol (mmol/L) 4.75 3.11 7.12
HDL cholesterol (mmol/L) 1.21 0.73 1.82
Triglycerides (mmol/L) 1.42 0.56 3.16
AST (U/L) 23.00 13.55 64.45
ALT (U/L) 31.00 12.00 84.45
GGT (U/L) 26.00 10.00 87.50
CHE (U/mL) 10066.37 5828.90 15084.55
Total bilirubin (휇mol/L) 9.41 4.28 20.94
Uric acid (mmol/L) 0.35 0.21 0.57
Albumin (g/dL) 4.30 3.60 4.90
Total Protein (g/dL) 7.56 6.76 8.30
Creatinine (휇mol/L) 70.72 44.20 106.08
Urea (mmol/L) 5.33 3.33 8.16
ALP (U/L) 76.00 42.75 247.75
C-peptide (ng/mL) 3.90 1.80 7.35
Insulin (mU/L) 19.00 6.90 53.03
HOMA 4.26 1.43 14.66
ALP: alkaline phosphatase; ALT: alanine transaminase; AST: aspartate
transaminase; BMI: Body Mass Index; BMR: basal metabolic rate; CHE:
cholinesterase; DBP: diastolic blood pressure; FFM: fat-free mass; FM: fat
mass; GGT: 훾-glutamyl transferase; HOMA: homeostatic model assessment;
RQ: respiratory quotient; SBP: systolic blood pressure; W/H: waist/hip.
amects the performance of mitochondrial ATP production
[11]. In fact, haplogroup T was reported to be more fre-
quent in white men with fertility problems (a condition
strongly dependent on ATP production) [13] and among
Spanish patients amected by len ventricular hypertrophy
[26]. Indeed, haplogroup T was less frequent among elite
endurance athletes (possibly related to a negative emect on
cardiac adaptation to endurance training) [11]. Amo et al.
[27] reported that mitochondrial bioenergetic capacities and
coupling ebciencies in cultured carcinoma cells did not dimer
between transmitochondrial cybrids harbouring mitochon-
dria with haplogroup H and those harbouring mitochondria
with haplogroup T [27]. However, the authors suggest that
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Table 2: Haplogroup frequencies in morbid obese patients (푛 =





subjects 푛 (%) 푃 OR/95% CI
H 233 (46.6) 88 (40.7)
I 7 (1.4) 6 (2.8)
J 25 (5.0) 21 (9.7) 0.02 0.63/0.45–0.89
K 29 (5.8) 18 (8.3)
T 66 (13.2) 13 (6.0) 0.004 1.94/1.16–3.22
JT 0 (0) 1 (0.5)
U 85 (17.0) 39 (18.1)
V 13 (2.6) 4 (1.9)
W 8 (1.6) 2 (0.9)
X 10 (2.0) 8 (3.7)
Others 24 (4.8) 16 (7.4)
this result could be partially inconclusive because the eYect of
mitochondrial haplogroupsmight be too small to be detected
by the procedures used [27], or they might need particular
nuclear genes in order to be expressed, or they might
need additional signals (nutrients and/or oxidative stress
molecules) to in^uence oxidative phosphorylation functions,
as previously described for the Uk haplogroup [28]. `e
foregoing studies suggest that, in our obese patients, the T
haplogroup could contribute to aYect the mechanisms of
energy balance regulation so leading to increased fat depots.
In conclusion, our anding that haplogroup T increases
the risk of obesity by about two-fold suggests that, besides
nuclear genome variations and environmental factors, the
T haplogroup contributes to morbid obesity in our study
population from southern Italy.
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